Sexual desire enhancing medicaments comprising benzimidazolone derivatives

• US 20070123540A1
• Filed: 10/19/2006
• Published: 05/31/2007
• Est. Priority Date: 10/29/2005
• Status: Abandoned Application

• Current Assignee: Angelo Ceci
• Original Assignee: Angelo Ceci
• Inventors: Ceci, Angelo
• Application Number:
  US11/550,869
• Publication Number:
  US 20070123540A1
• Time in Patent Office: Days
• US Class Current: 514/254.60
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/08 for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• CPC Class Codes: A61P 15/10 for impotence
• CPC Class Codes: A61P 15/12 for climacteric disorders

Abstract

The invention relates to the use of benzimidazolone derivatives of formula (I) for the preparation of a medicament for the treatment of sexual desire disorders.

Claims

1. A method of treating a sexual desire disorder comprising the administration of an effective amount of a compound of formula (I) to an individual

wherein R₁, R₂, R₃, and R₄ denote hydrogen or hydroxy with the proviso that R₁, R₂, R₃, and R₄ cannot simultaneously represent hydrogen, or a pharmacologically acceptable acid addition salt thereof.

2. The method according to claim 1, characterized in that the sexual desire disorder is selected from the group consisting of hypoactive sexual desire disorder, sexual aversion disorder loss of sexual desire, lack of sexual desire, decreased sexual desire, inhibited sexual desire, loss of libido, libido disturbance, and frigidity.

3. The method according to claim 2, characterized in that the sexual desire disorder is selected from the group consisting of hypoactive sexual desire disorder, sexual aversion disorder, loss of sexual desire, lack of sexual desire, decreased sexual desire, inhibited sexual desire.

4. The method according to claim 1, wherein the sexual desire disorder is a female sexual desire disorder.

5. The method according to claim 1, wherein the compound of formula (I) is in the form of a pharmaceutically acceptable acid addition salt, wherein the acid addition salt is selected from the salts formed by the acids selected from the group consisting of maleic, citric, tartaric, methanesulphonic, acetic, benzoic, succinic, gluconic, isethionic, glycinic, lactic, malic, mucoic, glutamic, sulphamic, ascorbic, hydrochloric, hydrobromic, nitric, sulfuric, phosphoric acid, and mixtures thereof.

6. The method according to claim 1, wherein the compound of formula (I) has a dosage range between 0.1 to 400 mg per day.

7. The method according to claim 1, wherein the compound of formula (I) is compound (I.a)

or a pharmacologically acceptable acid addition salt thereof.

8. The method according to claim 1, wherein the compound of formula (I) is compound (I.b)

or a pharmacologically acceptable acid addition salt thereof.

9. The method according to claim 1, wherein the compound of formula (I) is compound (I.c)

or a pharmacologically acceptable acid addition salt thereof.

10. The method according to claim 1, wherein the compound of formula (I) is compound (I.d)

or a pharmacologically acceptable acid addition salt thereof.

11. The method according to claim 1, wherein the compound of formula (I) is 1 compound (I.e)

or a pharmacologically acceptable acid addition salt thereof.

12. The method according to claim 1, wherein the compound of formula (I) is compound (I.f)

or a pharmacologically acceptable acid addition salt thereof.

13. The method according to claim 1, wherein the compound of formula (I) is compound (I.g)

or a pharmacologically acceptable acid addition salt thereof.

14. The method according to claim 1, wherein the compound of formula (I) is compound (I.h)

or a pharmacologically acceptable acid addition salt thereof.